ABR2AFR

International One Health Stakeholder Meeting on Antifungal Resistance

Fungal infections can cause severe, life-threatening diseases—but they often fly under the radar. 𝑫𝒊𝒅 𝒚𝒐𝒖 𝒌𝒏𝒐𝒘 𝒕𝒉𝒂𝒕 𝒐𝒏𝒍𝒚 6.5% 𝒐𝒇 𝒑𝒖𝒃𝒍𝒊𝒄 𝒂𝒏𝒅 𝒑𝒉𝒊𝒍𝒂𝒏𝒕𝒉𝒓𝒐𝒑𝒊𝒄 𝒊𝒏𝒗𝒆𝒔𝒕𝒎𝒆𝒏𝒕 𝒊𝒏 𝑨𝑴𝑹 𝑹&𝑫 𝒈𝒐𝒆𝒔 𝒕𝒐𝒘𝒂𝒓𝒅 𝒎𝒊𝒕𝒊𝒈𝒂𝒕𝒊𝒏𝒈 𝒇𝒖𝒏𝒈𝒂𝒍 infections?

From March 19–21, 2025, our Deputy Director, Ralf Sudbrak, joined John Rex and other experts at the International One Health Stakeholder Meeting (ABR2AFR) in Bilthoven, The Netherlands.

Meeting website: ABR2AFR – AMR Insights

Two key takeaways from the discussions:

1️⃣ New antifungals are urgently needed
2️⃣ Coordinated, multi-sectoral action is essential to protect both current and future antifungal treatments

The Hub tracks the landscape of funding for antifungal R&D globally.

💡 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧, 𝐜𝐡𝐞𝐜𝐤 𝐨𝐮𝐭:

📊 Global AMR R&D Hub Dashboard
📄 Dynamic Dashboard Factsheets – December 2024 – Global AMR R&D Hub